Targeted PROTAC delivery strategies overcome pharmacokinetic hurdles and systemic toxicity in cancer therapy
Background
Proteolysis-targeting chimeras (PROTACs) represent a groundbreaking therapeutic modality for cancer treatment by leveraging the ubiquitin-proteasome system (UPS) to degrade target proteins. Despite their promise, clinical translation is hampered by poor pharmacokinetic properties, limited tumor selectivity, and systemic toxicity. Current standard-of-care often lacks the precision to deliver these potent degraders specifically to tumor cells, necessitating advanced delivery systems to maximize efficacy and minimize off-target effects.
Study Design
This comprehensive review systematically analyzed active targeting strategies for PROTAC delivery, encompassing ligand-mediated approaches (aptamer-, antibody-, peptide-, and small-molecule-based conjugates), ligand-modified nanoparticle systems, and chemically engineered methods like CD36-dependent endocytosis. The authors established a unified mechanism-level comparative framework to assess each delivery modality across seven dimensions, examining both cytosol-directed and membrane-directed platforms, and evaluating their current clinical translation status.
Results
The review identified that targeted PROTAC delivery significantly enhances therapeutic selectivity and delivery efficiency by overcoming unfavorable pharmacokinetic properties and systemic toxicity. Key strategies include aptamer, antibody, peptide, and small-molecule conjugates, alongside nanoparticle systems, all designed to improve receptor-mediated cellular uptake.
A critical evaluation highlighted major translational challenges such as receptor heterogeneity, internalization efficiency, endosomal escape, tumor penetration, release control, manufacturing complexity, scalability, and safety considerations. The comparative framework revealed distinct architectural divides between cytosol-directed and membrane-directed platforms, providing practical design principles for rational PROTAC development. The analysis underscored the urgent need for advanced delivery systems to realize the full therapeutic potential of PROTACs in cancer therapy.
Key Findings
- Targeted PROTAC delivery strategies enhance therapeutic selectivity and delivery efficiency in cancer.
- Ligand-mediated approaches (aptamer, antibody, peptide, small molecule) are key for PROTAC conjugation.
- Nanoparticle systems and chemically engineered strategies improve receptor-mediated PROTAC uptake.
- Major translational challenges include receptor heterogeneity, endosomal escape, and manufacturing complexity.
- A comparative framework provides design principles for rational PROTAC development.
Why It Matters
This review provides a critical roadmap for researchers and developers aiming to translate PROTACs into effective clinical cancer treatments. Understanding the strengths and weaknesses of various delivery platforms is crucial for designing next-generation PROTACs with improved tumor specificity and reduced systemic toxicity. For biohackers and clinicians, this highlights the ongoing challenges in drug delivery and the potential for targeted approaches to unlock the full power of protein degradation. The insights into receptor heterogeneity and endosomal escape are particularly relevant for optimizing future PROTAC protocols and combination therapies, moving closer to a usable and safer therapeutic strategy.
protac
cancer
drug-delivery
nanoparticles
peptides
antibodies